Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-20478 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- SLITRK5 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A suggested positive control is NIH-3T3 cell lysate. PA5-20478 can be used with blocking peptide PEP-0598.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- 4°C, do not freeze
Submitted references MUC21 controls melanoma progression via regulating SLITRK5 and hedgehog signaling pathway.
Liu X, Xiao Y, Xiong X, Qi X
Cell biology international 2022 Sep;46(9):1458-1467
Cell biology international 2022 Sep;46(9):1458-1467
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry of Slitrk5 in human brain tissue with SLITRK5 Polyclonal Antibody (Product # PA5-20478) at 2.5 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence of slitrk5 in human brain tissue with SLITRK5 Polyclonal Antibody (Product # PA5-20478) at 20 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 2 Figure MUC21 suppressed SLITRK5 to regulate melanoma progression. (a) Heatmap of top 20 up/downregulated genes in MUC21 high expression patients in comparison with MUC21 low expression patients ( n = 462). (b) Western blotting of SLITRK5 in vector (VEC) or MUC21 overexpression (OE) A375/A875 cells. (c) Western blotting of SLITRK5 in vector (VEC) or SLITRK5 knockout (KO) A375/A875 cells. (d) Cell proliferation of vector (VEC) or SLITRK5 knockout (KO) A375/A875 cells. (e) Relative migrating cells of vector (VEC) or SLITRK5 knockout (KO) A375/A875 cells. (f) Immumohistochemical staining of SLITRK5 in melanoma patients divided into primary and metastatic groups ( n = 15 in each group). The scale bar was 100 mum. SLITRK5 expression was quantified
